Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesUroGen Pharma Ltd

UroGen Pharma Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
24.75 USD -0.98 ( 3.81%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1735106
Market Cap
2040.27M

Momentum Score

…

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
24.40
Low
26.34
High
52 Week Price Range
15.86
Low
50.81
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

UroGen Pharma is a commercial-stage biopharmaceutical company developing and marketing urology therapies using a proprietary sustained-release RTGel delivery platform; its lead product JELMYTO (mitomycin gel) is approved for low-grade upper tract urothelial carcinoma. Long-term growth may be supported by increased clinical adoption of JELMYTO, label expansion opportunities, pipeline programs leveraging RTGel and international rollout. The company appears positioned to address an underserved, rare urologic indication with a differentiated delivery technology.

Material risks include concentrated revenue from a single approved product, commercial execution and reimbursement challenges, clinical and regulatory uncertainty for new indications, and potential financing or cash-runway constraints that investors should monitor.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
25.73
Dividend Yield
-
Revenue TTM
188.73M
Revenue Per Share
3.81
Gross Profit TTM
171.46M
Debt / Equity
-1.22
ROE
-1481.26%
Net Debt
17.59M
ROCE
-89.63%
Diluted EPS TTM
-1.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -153.42M -124.04M -98.32M -108.03M -109.37M
Net income -153.49M -126.87M -102.24M -109.16M -110.82M
Selling general administrative 155.10M 121.15M 90.36M 82.84M 39.94M
Selling and marketing expenses - - - - 47.59M
Gross profit 97.34M 81.52M 73.35M 56.70M 42.88M
Reconciled depreciation 2.41M 1.19M 1.73M 1.82M 1.77M
Ebit -138.07M -95.68M -62.06M -79.04M -92.29M
Ebitda -135.66M -95.35M -60.35M -78.03M -75.00M
Depreciation and amortization 2.41M 0.33M 1.71M 1.01M 17.29M
Non operating income net other - - - 1.01M 0.21M
Operating income -124.86M -96.78M -65.54M -79.04M -92.29M
Other operating expenses 234.65M 187.18M 148.25M 143.40M 140.33M
Interest expense 33.85M 12.52M 14.71M 8.44M 32.60M
Tax provision 0.08M 2.83M 0.76M 1.75M 1.45M
Interest income 5.96M 8.90M 2.38M 0.94M 0.36M
Net interest income -27.88M -3.62M -11.90M -7.43M 0.21M
Income tax expense 0.08M 2.83M 3.92M 1.14M 1.45M
Total revenue 109.79M 90.40M 82.71M 64.36M 48.04M
Total operating expenses 222.20M 178.30M 138.89M 135.74M 135.18M
Cost of revenue 12.45M 8.88M 9.36M 7.65M 5.16M
Total other income expense net -28.55M -27.26M -32.79M -28.99M -17.08M
Net income from continuing ops -153.49M -126.87M -105.10M -109.78M -110.82M
Net income applicable to common shares - - - -109.78M -110.82M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 200.46M 285.71M 178.31M 136.24M 119.75M
Other current assets 16.02M 9.92M 10.28M 11.10M 7.48M
Total liab 305.93M 294.51M 243.52M 224.98M 111.33M
Total stockholder equity -105.47M -8.80M -65.21M -88.74M 8.41M
Other current liab 34.28M 35.02M 19.49M 18.39M 16.59M
Common stock 0.13M 0.12M 0.09M 0.06M 0.06M
Capital stock 0.13M 0.12M 0.09M 0.06M 0.06M
Retained earnings -959.72M -806.22M -679.35M -577.10M -467.32M
Other liab - - - - 88.56M
Other assets - - - 0.62M 0.03M
Cash 110.75M 171.99M 95.82M 55.41M 44.36M
Total current liabilities 46.42M 45.95M 31.21M 23.92M 22.38M
Current deferred revenue - 5.15M 4.39M - -
Net debt 17.59M -48.60M 4.39M 43.72M -43.96M
Short term debt - 1.53M 0.82M - -
Short long term debt total 128.33M 123.39M 100.21M 99.12M 0.40M
Other stockholder equity 854.09M 797.25M 614.03M 488.41M 475.70M
Property plant equipment - - - 1.30M 1.97M
Total current assets 186.02M 276.13M 169.19M 128.91M 114.39M
Long term investments 0.00M 5.02M 4.50M 0.00M 0.68M
Net tangible assets - - - -89.36M 8.41M
Short term investments 9.71M 64.70M 41.97M 44.56M 44.78M
Net receivables 33.08M 20.30M 15.44M 12.70M 11.72M
Long term debt 122.21M 121.73M 98.55M 97.54M -
Inventory 16.46M 9.23M 5.67M 4.33M 4.83M
Accounts payable 12.14M 10.93M 6.51M 5.53M 5.79M
Accumulated other comprehensive income 0.02M 0.06M 0.01M -0.11M -0.03M
Common stock total equity - - - 0.06M 0.06M
Retained earnings total equity - - - -577.10M -467.32M
Non currrent assets other 5.16M 0.77M 2.04M 2.96M 1.53M
Non current assets total 14.43M 9.58M 9.12M 6.71M 5.36M
Capital lease obligations 6.12M 1.65M 0.84M 1.59M 0.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 61.85M -20.61M 33.50M 1.31M 4.82M
Change to liabilities - - - 0.89M -0.56M
Total cashflows from investing activities 61.56M -20.61M -0.95M 1.06M 4.07M
Net borrowings -1.85M 24.49M 0.00M 95.78M -
Total cash from financing activities 39.92M 194.62M 116.93M 97.13M 72.32M
Change to operating activities - - - - -7.69M
Net income -153.49M -126.87M -102.24M -109.78M -110.82M
Change in cash -60.97M 77.24M 39.60M 10.63M -8.50M
Begin period cash flow 173.06M 95.82M 56.22M 45.59M 54.09M
End period cash flow 112.09M 173.06M 95.82M 56.22M 45.59M
Total cash from operating activities -162.44M -96.77M -76.38M -87.56M -84.89M
Issuance of capital stock 39.80M 151.17M 67.36M - 0.00M
Depreciation 2.41M 1.19M 1.71M 1.82M 1.77M
Change to inventory -7.24M -3.55M -1.35M -0.36M -2.87M
Change to account receivables -12.78M -4.86M -2.74M -0.99M -4.67M
Sale purchase of stock - - - 1.35M -0.08M
Other cashflows from financing activities 39.92M 18.96M 49.57M 97.13M 72.32M
Change to netincome - - - 11.45M 23.11M
Capital expenditures 0.29M 0.29M 0.19M 0.25M 0.75M
Change receivables - - - -0.99M -4.67M
Cash flows other operating - - - 9.06M 9.61M
Cash and cash equivalents changes - - - 10.63M -8.50M
Change in working capital -27.91M 4.93M 3.34M -6.31M -13.11M
Stock based compensation 11.96M 13.11M 9.34M 10.58M 23.11M
Other non cash items 4.59M 10.88M 11.48M 16.13M -1.18M
Free cash flow -162.73M -97.06M -76.57M -87.81M -85.64M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
URGN
UroGen Pharma Ltd		 -0.98
3.81%		 24.75 - 37.17 11.04 19.27 11.43 -2.63
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

400 Alexander Park Drive, Princeton, NJ, United States, 08540

646 768 9780

https://www.urogen.com

300

Name Title Year Born
Ms. Elizabeth A. Barrett Pres, CEO & Director 1962
Mr. Jason Drew Smith Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1972
Dr. Mark P. Schoenberg M.D. Chief Medical Officer 1958
Mr. Dong Kim Chief Financial Officer 1977
Vincent I. Perrone Sr. Director of Investor Relations NA
Eric Van Zanten Sr. Director of Communications NA
Dr. Sari Prutchi-Sagiv Ph.D. Marketing Director NA
Dr. Marina Konorty Exec. VP of R&D and Technical Operations NA
Mr. Jeffrey Bova M.B.A. Chief Commercial Officer NA
Mr. James Ottinger R.ph. Exec. VP of Regulatory Affairs & Quality NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…